TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12422579
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg + clarithromycin 500 mg + metronidazole 500 mg (OCM)
Study: 9122012
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment in group I (61 patients with glomerular disease at diagnosis)
Study: 9122012
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment in group II (24 patients with restrained disease activity)
Study: 9122012
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment in group III (14 patients with active glomerulopathy)
Study: 9122012
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of IC
Study: 9122012
Drug: Simultaneous excretion
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous excretion of C4 in urine
Study: 1745621
Drug: 500-mg ETA
Normalized name: .MU.-METHYLENE-.MU.-CHLOROBIS(.ETA.5-2,4-CYCLOPENTADIEN-1-YL)(DIMETHYLALUMINUM)TITANIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mg ETA suppository
Study: 1745621
Drug: 250-mg ETA
Normalized name: .MU.-METHYLENE-.MU.-CHLOROBIS(.ETA.5-2,4-CYCLOPENTADIEN-1-YL)(DIMETHYLALUMINUM)TITANIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250-mg ETA tablets
Study: 1745621
Drug: Two placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tablets
Study: 7035987
Drug: Propranolol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (320 mg given in 8 doses over a period of 24 hours)
Study: 30684965
Drug: Curcumin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin plus placebo (CC)
Study: 30684965
Drug: Curcumin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin plus long-chain omega-3 polyunsaturated fatty acids (CC-FO)
Study: 28320856
Drug: Baroreflex activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex activation therapy
Study: 17228169
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with standardized, aluminum hydroxide‐adsorbed J. ashei extract (100 IR, 54 microg of Jun a 1/ml)
Study: 8646573
Drug: Dye laser
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dye laser treatment
Study: 3434348
Drug: Chloramphenicol treatment
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol treatment continued after negative cultures
Study: 3434348
Drug: Chloramphenicol treatment
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol treatment withdrawn after negative cultures
Study: 27792719
Drug: Surgical debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical debridement and topical application of silver sulfadiazine (SSD)
Study: 25523578
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) treatment for 1 week
Study: 25523578
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) treatment for 2 weeks
Study: 22646167
Drug: CAO +
Normalized name: Gan Cao Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAO + S (simvastatin 20 mg)
Study: 20621700
Drug: Standard duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard duration therapy (24 weeks)
Study: 20621700
Drug: Variable duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable duration therapy (VD12 for 12 weeks and VD24 for 24 weeks)
Study: 20621700
Drug: Variable duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable duration therapy (VD12 for 12 weeks)
Study: 20621700
Drug: Variable duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable duration therapy (VD24 for 24 weeks)
Study: 17826201
Drug: Active TSE
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TSE treatment
Study: 17826201
Drug: Sham TSE
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham TSE treatment
Study: 17826201
Drug: Active and
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active and Sham TSE treatments
Study: 10578484
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (350 mg)
Study: 10578484
Drug: RRR-alpha-tocopherol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopherol (250 mg)
Study: 10578484
Drug: Beta-carotene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (60 mg)
Study: 10578484
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (350 mg) + RRR-alpha-tocopherol (250 mg)
Study: 8722735
Drug: Patient-controlled morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled morphine consumption (mg)
Study: 1914760
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg by mouth 2 hr before the start)
Study: 6350957
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g of ornidazole
Study: 6350957
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g of ornidazole
Study: 6350957
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of ornidazole
Study: 28270284
Drug: Saline flush
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline flush at 3.0 ml/s (40 ml) - Group A
Study: 28270284
Drug: Saline flush
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline flush at 4.0 ml/s (40 ml) - Group B
Study: 26846324
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (50 mg/day)
Study: 17674476
Drug: Combined antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antiviral therapy (CAT)
Study: 25675557
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment (control group)
Study: 8942410
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (7.2 g per day)
Study: 1916166
Drug: Per-rectal pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per-rectal pulsed irrigation
Study: 1916166
Drug: Per-oral colonic
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per-oral colonic lavage
Study: 6345426
Drug: Conalbumin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conalbumin plus traditional dietetic therapy
Study: 6345426
Drug: Traditional dietetic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dietetic therapy
Study: 24716847
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel 300 mcg/day
Study: 27628323
Drug: JE-CV booster
Normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Injectable Suspension [Je-Vax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-CV booster dose
Study: 18194330
Drug: 5000 ppm
Normalized name: Sodium Fluoride 5000 PPM
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5000 ppm F-toothpaste used twice a day
Study: 18194330
Drug: 1450 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1450 ppm F-toothpaste used twice a day
Study: 17663803
Drug: Dietary portfolio
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary portfolio high in plant sterols (1 g/4200 kJ), soya proteins (21.4 g/4200 kJ), soluble fibres (9.8 g/4200 kJ) and almonds (14 g/4200 kJ)
Study: 16398595
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lovastatin
Study: 1524078
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 250 mg twice daily (n = 157)
Study: 1524078
Drug: Amoxicillin/clavulanate 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 500 mg three times daily (n = 160)
Study: 1524078
Drug: Amoxicillin/clavulanate 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 500 mg three times daily
Study: 6406442
Drug: Bupropion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (150 or 450 mg/day)
Study: 6406442
Drug: Imipramine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (up to 200 mg/day)
Study: 29912913
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules containing Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14
Study: 17676423
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (5.2 g daily)
Study: 9673809
Drug: S-fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-fluoxetine
Study: 8033434
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immune globulin (IVIG)
Study: 2917360
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg 4-OHA orally once, twice, and 4 times daily for 2 weeks
Study: 2917360
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg i.m. every 2 weeks
Study: 2917360
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg 4-OHA orally 4 times daily
Study: 2917360
Drug: Parenteral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral treatment
Study: 23685080
Drug: Traction with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traction with a 500 mL weighted bag
Study: 17302684
Drug: Antiarrhythmic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic therapy (preferably amiodarone)
Study: 11173143
Drug: Conformal radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conformal radiotherapy with dose escalation
Study: 9744780
Drug: Weekly 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 5‐FU 600 mg/m2 i.v. bolus (30 patients)
Study: 9744780
Drug: Weekly 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 5‐FU 600 mg/m2 bolus plus leucovorin (LV) 500 mg/m2 2‐h i.v. infusion (28 patients)
Study: 9744780
Drug: Weekly 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 5‐FU 2600 mg/m2 24‐h continuous i.v. infusion plus LV 100 mg 4‐h i.v. infusion and 50 mg orally every 4 h for five doses (24 patients)
Study: 31377776
Drug: Aspirin or
Normalized name: aspirin Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or transoesophageal echocardiogram prior to cardioversion
Study: 31377776
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral anticoagulation or transoesophageal echocardiogram prior to cardioversion
Study: 31377776
Drug: Aspirin or
Normalized name: aspirin Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or aspirin plus clopidogrel
Study: 606768
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (200 chick cell-agglutinating units/0.5-ml dose)
Study: 606768
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination (40 chick cell-agglutinating units/0.1-ml dose)
Study: 30989788
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of misoprostol (Cytotec®)
Study: 28623755
Drug: Adjunctive lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive lacosamide (LCM)
Study: 28623755
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (≥2 AEDs with stable dosing)
Study: 26308294
Drug: Hydrocortisone 50
Normalized name: hydrocortisone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 50 mg twice daily for 1 week
Study: 26308294
Drug: Placebo 50
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 50 mg twice daily for 1 week
Study: 18648227
Drug: Sugammadex 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 16 mg/kg administered 3 min after 1.0 mg/kg rocuronium
Study: 18648227
Drug: Sugammadex 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 16 mg/kg administered 15 min after 1.0 mg/kg rocuronium
Study: 18648227
Drug: Sugammadex 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 16 mg/kg administered 3 min after 1.2 mg/kg rocuronium
Study: 18648227
Drug: Sugammadex 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 16 mg/kg administered 15 min after 1.2 mg/kg rocuronium
Study: 9262298
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (LDA) 50 mg/day
Study: 9336321
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine (100 mg)
Study: 8371143
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine (100 mg) with alcohol (1 g/kg)
Study: 8371143
Drug: Alcohol alone
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol alone (1 g/kg)
Study: 27461846
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate 200 mg IV
Study: 28865799
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate 200 mg PO
Study: 27461846
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate 200 mg (multiple dosing)
Study: 27461846
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate 200 mg
Study: 25402495
Drug: Zirconium cyclosilicate
Normalized name: ZIRCONIUM CYCLOSILICATE ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zirconium cyclosilicate 5 g daily for 28 days
Study: 25402495
Drug: Zirconium cyclosilicate
Normalized name: ZIRCONIUM CYCLOSILICATE ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zirconium cyclosilicate 10 g daily for 28 days
Study: 25402495
Drug: Zirconium cyclosilicate
Normalized name: ZIRCONIUM CYCLOSILICATE ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zirconium cyclosilicate 15 g daily for 28 days
Study: 18818174
Drug: 1% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% glucose acetated Ringer solution containing Mg2+
Study: 18818174
Drug: Glucose free
Normalized name: Glucose free hemofiltration solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose free solution containing Na+ 130 mEq/L without Mg2+
Study: 8935809
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ziprasidone
Study: 1913698
Drug: Sinemet CR
Normalized name: Sinemet CR
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sinemet CR (50-200) controlled-release tablets
Study: 1913698
Drug: Standard Sinemet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Sinemet (25-100) immediate-release tablets
Study: 6409316
Drug: Combined measles,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined measles, mumps, and rubella vaccine (two different batches)
Study: 26817809
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training at 30% of maximal inspiratory pressure for 15 minutes twice a day, 7 days a week, for 12 weeks alongside standard medical treatment.
Study: 26817809
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment only (control group).
Study: 24837137
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m²) with zoledronic acid (group DZ)
Study: 24837137
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m²) without zoledronic acid (group D)
Study: 9543976
Drug: hyper-oxygenated fatty
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyper-oxygenated fatty acid esters solution
Study: 2898536
Drug: Combined-modality therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality therapy (chemotherapy plus radiotherapy)
Study: 2898536
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (SMF: streptozocin, mitomycin, and 5-fluorouracil)
Study: 2898536
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (SMF)
Study: 21639810
Drug: Ipilimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (10 mg per kilogram) plus dacarbazine (850 mg per square meter)
Study: 21639810
Drug: Dacarbazine (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine (850 mg per square meter) plus placebo
Study: 14748941
Drug: Antioxidant mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant mixture (Se 150 microg, retinyl acetate mg, ascorbic acid 120 mg, alpha‐tocopheryl succinate 20 mg)
Study: 8198414
Drug: Ethamsylate (165
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethamsylate (165 infants received the drug)
Study: 2830918
Drug: 4-aminopyridine (4-AP)
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (4-AP) 2.5 mg b.i.d.
Study: 2830918
Drug: 4-aminopyridine (4-AP)
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (4-AP) 5 mg b.i.d.
Study: 2830918
Drug: 4-aminopyridine (4-AP)
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (4-AP) 10 mg b.i.d.
Study: 30187572
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of 2% lidocaine solution 20mL (LID, n=64)
Study: 29364340
Drug: Antibiotic (Azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic (Azithromycin 500mg)
Study: 20626422
Drug: Conventionally placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventionally placed submerged implants (Group 1)
Study: 20626422
Drug: Early-placed submerged
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early-placed submerged implants (Group 2)
Study: 20626422
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 implants
Study: 20626422
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 implants
Study: 31107344
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (SCIG), a 20% solution stabilized with L‐proline, FDA-approved for CIDP maintenance therapy.
Study: 19403902
Drug: T12PR24 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: T12PR24 group (telaprevir 1250 mg on day 1 and 750 mg every 8 hours for 12 weeks, plus peginterferon alfa‐2a and ribavirin for 24 weeks)
Study: 8011392
Drug: 0.1 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mmol/kg gadodiamide injection
Study: 8011392
Drug: 0.3 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mmol/kg gadodiamide injection
Study: 8011392
Drug: Overall diagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall diagnostic utility of gadodiamide injection
Study: 8011392
Drug: Safety profile
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety profile of gadodiamide injection
Study: 27778151
Drug: Low dietary
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dietary intake of magnesium (<250 mg/day)
Study: 27778151
Drug: High dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dietary intake of magnesium (>250 mg/day)
Study: 25055838
Drug: DMCT (dose-matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMCT (dose-matched control treatment)
Study: 24210600
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) therapy for 12 weeks
Study: 22101701
Drug: SGIP acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGIP acupuncture therapy
Study: 11602221
Drug: Propranolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (beta 1 and beta 2 receptor antagonist)
Study: 11602221
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion before an injection of placebo
Study: 29873956
Drug: MIN‐101 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIN‐101 32 mg
Study: 29873956
Drug: MIN‐101 64
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIN‐101 64 mg
Study: 19930762
Drug: HFrD (hypercaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFrD (hypercaloric diet enriched with fructose, 3.5 g fructose/kg fat‐free mass per day, +35% energy intake)
Study: 19930762
Drug: HGlcD (hypercaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGlcD (hypercaloric diet enriched with glucose, 3.5 g glucose/kg fat‐free mass per day, +35% energy intake)